MRK dividend yield: 3.25%. MET dividend yield: 4.00%. Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s. MET is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in MET shares.
Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
MET is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in MET shares.
MRK currently offers a 3.25% yield (3.08/share/year) while MET offers 4.00% (2.00/share/year). MET provides higher current income. However, MRK has grown its dividend faster (8.2% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in MRK vs MET earn per year?
With $10,000 invested today: MRK pays approximately $325/year. MET pays approximately $400/year. With DRIP reinvestment over 10 years, these grow to $950/year (MRK) and $899/year (MET).
Does MRK or MET pay monthly dividends?
MRK pays quarterly dividends. MET pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this MRK vs MET comparison by email
Save your analysis + get weekly dividend insights. Free forever.